1314 ET - Hims & Hers' launch of generic liraglutide is likely to contribute more to the telehealth platform's growth than offering Eli Lilly's Zepbound, Leerink Partners analyst Michael Cherny tells WSJ. The liraglutide launch comes a month earlier than expected and could help boost quarterly revenue, as the company is looking for alternatives to its compounded semaglutide drug, which the FDA is cracking down on now that shortages of GLP-1s are over. Liraglutide falls more in line with Hims business model of offering affordable treatments, Cherney says, as it would cost around $299 a month vs. $1,899 a month for Zepbound.(katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:14 ET (17:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。